Mescaline
In clinical developmentAlso known as 2-(3,4,5-trimethoxyphenyl)ethanamine, 3,4,5-trimethoxyphenethylamine.
Recent clinical, regulatory, research and industry developments relating to this drug.
Cardiovascular safety of psychedelic medicine: current status and future directions.
Role of the Serotonin 5-HT2A Receptor in Mescaline-induced Altered States of Consciousness
Psychedelic Drug Legislative Reform and Legalization in the US.
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Recent completions
Trials that read out recently, adding to the completed evidence base.
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Major research themes3
Journals, researchers & institutions
- JAMA psychiatry1
- Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology1
- Pharmacological reports : PR1
- Arikci D1
- Becker AM1
- Coviello F1
- Daily JE1
- Dierbach S1
- Duthaler U1
- Eckert A1
- Holze F1
- Center for Empirical Research in the Law1
- Chair and Department of Experimental and Clinical Physiology1
- Clinical Pharmacology and Toxicology1
- Psychiatric University Hospital1
- University of Basel1
- Washington University in St Louis1
Related drugs
Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).
Studied across the same disease area as Mescaline in the shared literature.
Studied across the same disease area as Mescaline in the shared literature.
- RxNorm (U.S. National Library of Medicine) — drug identity
- ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
- Europe PMC — research literature
- ClinicalTrials.gov — clinical trials